Fate Therapeutics, Inc. ( FATE) - Stock Earnings
FATE Upcoming earnings
Estimated EPS and revenue columns are available to paid members.
| Date | EPS (actual / est.) | Revenue low (est.) | Revenue (actual / est.) | Revenue high (est.) |
|---|---|---|---|---|
| Nov. 12, 2026, midnight | — / — | — | — / — | — |
FATE Quarterly earnings
Analyst consensus estimates are available to paid members.
| Date | Earnings | Revenue |
|---|---|---|
| 2025Q4 | -32.4 million USD | 1.4 million USD |
| 2026Q1 | -31.2 million USD | 1.3 million USD |
| 2026Q2 | -30.2 million USD | 2.1 million USD |
| 2026Q4 Est. | — | — |
| 2027Q1 Est. | — | — |
| 2027Q2 Est. | — | — |
FATE Yearly earnings
Analyst consensus estimates are available to paid members.
| Date | Earnings | Revenue |
|---|---|---|
| 2023 | -160.9 million USD | 63.5 million USD |
| 2024 | -186.3 million USD | 13.6 million USD |
| 2025 | -136.3 million USD | 6.6 million USD |
| 2026 Est. | — | — |
FATE
Price: $1.79
52 week price:
Earnings Per Share: -1.09 USD
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 1.6 million
Ebitda: -10.1 millionMarket Capitalization: 278.0 million